Asthika Goonewardene Analyst Performance

Managing Director, Senior Biotech Analyst at Truist Financial

Asthika Goonewardene is a stock analyst at Truist Financial focused in the medical sector, covering 18 publicly traded companies. Over the past year, Asthika Goonewardene has issued 31 stock ratings, including strong buy, buy, and hold recommendations. While full access to Asthika Goonewardene's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Asthika Goonewardene's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 40 Last 5 Years
Buy Recommendations: 77.14% 27 Buy Ratings
Companies Covered: 18 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	5.7%	2 ratings
Buy	71.4%	25 ratings
Hold	22.9%	8 ratings
Sell	0.0%	0 ratings

Out of 35 total stock ratings issued by Asthika Goonewardene at Truist Financial, the majority (71.4%) have been Buy recommendations, followed by 22.9% Hold and 5.7% Strong Buy.

Best & Worst Calls

Best Call
000.0%
GMAB
Mar 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
CELU
Oct 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	94.4% of companies on NASDAQ	17 companies
NYSE	5.6% of companies on NYSE	1 company

Asthika Goonewardene, an analyst at Truist Financial, currently covers 18 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 17 companies	94.4%
	Manufacturing 1 company	5.6%

Asthika Goonewardene of Truist Financial specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 17 companies	94.4%
PHARMACEUTICAL PREPARATIONS 1 company	5.6%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
BNTX BioNTech	3/25/2026	Upgrade	$88.77		Strong-Buy
LEGN Legend Biotech	3/20/2026	Downgrade	$17.41		Hold
BNTX BioNTech	3/10/2026	Set Price Target	$83.89	$155.00
LEGN Legend Biotech	3/10/2026	Set Price Target	$19.52	$70.00
LEGN Legend Biotech	3/10/2026	Upgrade	$19.05		Strong-Buy
ACLX Arcellx	2/23/2026	Downgrade	$114.10	$120.00	Hold
ACLX Arcellx	2/23/2026	Downgrade	$113.75	$120.00	Hold
EXEL Exelixis	1/14/2026	Set Price Target	$44.55	$51.00
ZYME Zymeworks	12/17/2025	Initiated Coverage	$25.85	$40.00	Buy
RCUS Arcus Biosciences	12/12/2025	Set Price Target	$22.07	$30.00
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
AVBP ArriVent BioPharma	11/25/2025	Initiated Coverage	$21.51	$43.00	Buy
AVBP ArriVent BioPharma	11/25/2025	Initiated Coverage	$22.78	$43.00	Buy
GILD Gilead Sciences	11/24/2025	Initiated Coverage	$127.67	$140.00	Buy
MRSN Mersana Therapeutics	11/13/2025	Downgrade	$27.67	$30.75	Hold
GMAB Genmab A/S	11/6/2025	Reiterated Rating	$28.84	$48.00	Buy
CRBU Caribou Biosciences	11/4/2025	Set Price Target	$2.43	$7.00
GILD Gilead Sciences	11/3/2025	Reiterated Rating	$120.58	$145.00	Buy
RCUS Arcus Biosciences	10/7/2025	Reiterated Rating	$14.54	$39.00	Buy
MRUS Merus	9/29/2025	Downgrade	$93.81	$97.00	Hold
JANX Janux Therapeutics	9/10/2025	Initiated Coverage	$23.78	$100.00	Buy
RVMD Revolution Medicines	9/5/2025	Initiated Coverage	$38.95	$99.00	Buy
MRSN Mersana Therapeutics	8/14/2025	Lower Price Target	$7.65	$36.00	Buy
GILD Gilead Sciences	8/8/2025	Upgrade	$110.28	$127.00	Buy
EXEL Exelixis	7/29/2025	Lower Price Target	$37.22	$49.00	Buy
EXEL Exelixis	7/15/2025	Boost Price Target	$44.47	$56.00	Buy
GMAB Genmab A/S	7/8/2025	Boost Price Target	$21.33	$46.00	Buy
EXEL Exelixis	6/23/2025	Reiterated Rating	$43.61	$55.00	Buy
BNTX BioNTech	6/3/2025	Reiterated Rating	$116.20	$155.00	Buy
MRSN Mersana Therapeutics	5/16/2025	Boost Price Target	$8.33	$250.00	Buy
LEGN Legend Biotech	5/14/2025	Lower Price Target	$28.41	$71.00	Buy
ALLO Allogene Therapeutics	5/14/2025	Lower Price Target	$0.93	$10.00	Buy
GMAB Genmab A/S	3/11/2025	Lower Price Target	$20.25	$45.00	Buy
IOVA Iovance Biotherapeutics	3/3/2025	Lower Price Target	$4.09	$15.00	Buy
CRGX CARGO Therapeutics	1/30/2025	Downgrade	$13.19	$7.00	Hold
EXEL Exelixis	1/27/2025	Boost Price Target	$32.99	$43.00	Buy
EXEL Exelixis	1/15/2025	Boost Price Target	$36.78	$42.00	Buy

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.